查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813234

2032 年人工智慧肿瘤映射市场预测：按癌症类型、技术、应用、最终用户和地区进行的全球分析

AI Tumor Evolution Maps Market Forecasts to 2032 - Global Analysis By Cancer Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 AI 肿瘤映射市场预计在 2025 年达到 1.9603 亿美元，到 2032 年将达到 13.9077 亿美元，预测期内的复合年增长率为 32.3%。

人工智慧肿瘤进展图谱是一套创新系统，旨在研究癌症如何随时间推移发展、变异以及对不同治疗的反应。这些图谱处理广泛的基因组图谱、医学扫描和患者记录，以揭示肿瘤进展的动态特性。透过揭示癌细胞如何适应和获得抗药性，它们可以帮助研究人员预测临床结果并制定个人化治疗方案。与传统方法不同，人工智慧主导的模型整合了多种数据集，揭示了肿瘤生物学中原本可能隐藏的微妙相互作用。这种前沿方法为肿瘤学家提供了更深入的洞察，使他们能够做出更精准的治疗决策，并改善癌症管理的前景。

根据国际癌症研究机构（IARC）的数据，预计癌症相关死亡人数将从 2008 年的 760 万人增加到 2030 年的 1,300 万人。

癌症发生率增加

全球癌症患者数量的成长极大地推动了对人工智慧肿瘤进展图谱的需求。随着越来越多的患者确诊，医疗保健系统需要先进的工具来追踪肿瘤生长、预测变化并支持个人化治疗决策。基于人工智慧的图谱使临床医生能够处理大量的基因组和临床数据集，从而增强护理管理。人们对癌症风险和治疗方案的认识不断提高，以及癌症类型的不断增加，进一步刺激了这些技术的普及。这种情况正在推动对支持早期发现、制定针对性治疗策略和提高患者存活率的人工智慧解决方案的投资，使其成为现代肿瘤学实践中不可或缺的一部分。

实施成本高

实施人工智慧肿瘤映射的高昂成本是市场发展的一大限制因素。建置和维护此类系统需要在计算硬体、软体解决方案和熟练的专业人员方面投入巨额资金。规模较小的医疗机构通常无法负担这些成本，从而限制了其使用人工智慧肿瘤映射技术。软体更新、资料管理以及与现有临床工作流程整合相关的额外费用进一步加剧了这项挑战。这些经济障碍可能会减缓市场成长，限制新竞争对手的进入，并阻碍其在新兴市场的普及。儘管人工智慧肿瘤映射工具具有诸多优势，但高昂的实施成本仍是阻碍其在全球医院和诊所广泛应用的重要因素。

精准肿瘤学需求不断成长

精准肿瘤学日益增长的兴趣为AI肿瘤映射市场提供了巨大的成长潜力。患者和医疗保健提供者都越来越寻求个人化治疗方法，这些方法可以考虑个别肿瘤特征、基因变异和治疗结果。基于AI的肿瘤映射平台可以分析复杂讯息，检测细微模式，并为客製化治疗产生可行的建议。随着精准医疗的普及，对支持精准预后、优化治疗和预测抗药性的AI工具的需求日益增长。透过利用这一需求，基于AI的肿瘤映射解决方案提供者可以扩大其市场范围，改善患者照护，并在全球范围内推进靶向癌症治疗的实施。

与传统方法的竞争

传统的癌症诊断和监测技术对AI肿瘤进展图谱市场构成了威胁。传统方法，例如切片检查、病理学检查和标准成像技术，已经成熟、可靠，并且通常比AI主导的平台更实惠。医疗保健提供者可能会因为对准确性、工作流程整合和培训要求的担忧而犹豫是否采用新的AI技术。这种不愿意采用新方法的态度可能会减缓AI肿瘤进展解决方案的市场渗透速度，尤其是在资源有限的地区。传统方法也受益于监管部门的核准经验和广泛的临床检验。因此，AI平檯面临着来自传统方法的激烈竞争，儘管存在潜在的技术改进，但这可能会限制它们的采用。

COVID-19的影响：

COVID-19疫情对AI肿瘤映射市场产生了显着影响。许多医院和研究中心的常规癌症护理（包括筛检、监测和临床研究）中断，暂时减少了对基于AI的肿瘤映射系统的需求。供应链延迟进一步阻碍了必要硬体和软体的部署。相反，疫情加速了数位健康解决方案、远端医疗和AI分析的整合，彰显了远端监控和预测性医疗工具的关键作用。虽然短期市场成长因此放缓，但COVID-19疫情凸显了AI肿瘤映射平台在改善病患管理、增强决策能力和增强医疗韧性方面的重要性。

预计乳癌将成为预测期内最大的癌症类别

预计乳癌领域将在预测期内占据最大的市场份额。这种主导地位源于全球乳癌的高发病率以及旨在改善乳癌治疗的人工智慧研究的大量投资。包括深度学习模型和先进影像技术在内的人工智慧驱动工具显着改善了乳癌患者早期检测、个人化治疗策略以及肿瘤发展的持续监测。随着人工智慧技术的不断发展，其在乳癌的应用预计将不断扩展，从而巩固其在人工智慧肿瘤映射市场中的主导地位。

预计人工智慧和健康科技新兴企业领域在预测期内的复合年增长率最高

预计人工智慧与健康科技新兴企业领域将在预测期内实现最高成长率。这一增长将由个人化医疗领域的创新推动，人工智慧可根据个人的基因资讯、生活方式和健康史量身定制治疗方案。此外，这些新兴企业正在率先将人工智慧与基因组学和临床数据相结合，提供创新的解决方案，显着提高癌症诊断和治疗策略的准确性和有效性。他们的适应能力和对尖端技术的专注，使其成为快速推进人工智慧肿瘤学领域的关键参与者。

比最大的地区

预计北美将在预测期内占据最大的市场份额。其领先地位得益于先进的医疗设施、巨额的研发投入以及较高的癌症发生率等因素。包括优惠法规和倡议创造了一个强大的生态系统。

复合年增长率最高的地区：

预计亚太地区在预测期内的复合年增长率最高。这一快速增长得益于癌症患病率上升、医疗基础设施改善以及人工智慧在医疗诊断中的应用日益广泛等因素。中国、日本和印度等国家正大力投资人工智慧研发，为市场成长创造了有利环境。此外，医疗机构与科技公司之间的伙伴关係也促进了人工智慧解决方案在肿瘤学领域的整​​合。这些因素共同作用，使亚太地区成为全球人工智慧肿瘤映射市场的主要参与者。

提供免费客製化

订阅此报告的用户将获得以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章全球人工智慧肿瘤映射市场（按癌症类型）

  • 脑肿瘤
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 摄护腺癌
  • 胰臟癌
  • 造血系统恶性肿瘤
  • 罕见癌症和儿童癌症
  • 其他癌症类型

6. 全球人工智慧肿瘤映射市场（按技术）

  • 基于影像的映射（MRI、CT、PET）
  • 基因组和转录组图谱
  • 人工智慧预测模型
  • 多组体学整合平台
  • 空间转录组学
  • 数位双胞胎建模
  • 联邦学习和隐私保护人工智慧

7. 全球人工智慧肿瘤映射市场（按应用）

  • 诊断和早期检测
  • 预后和风险评估
  • 治疗计划
  • 药物开发和临床试验
  • 肿瘤监测和復发预测
  • 生物标记发现
  • 免疫治疗中的患者分层

8. 全球人工智慧肿瘤映射市场（按最终用户）

  • 医院和诊所
  • 研究所
  • 製药和生物技术公司
  • 学术机构
  • 诊断实验室
  • 人工智慧和健康科技Start-Ups

9. 全球人工智慧肿瘤映射市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Azra AI
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Median Technologies
  • PathAI
  • Paige
  • AstraZeneca
  • CancerIQ
  • X-ZELL
  • MNM Bioscience
  • Biotome
  • Immunai
  • OncoHost
  • Tempus
  • 1Cell.Ai
Product Code: SMRC30693

According to Stratistics MRC, the Global AI Tumor Evolution Maps Market is accounted for $196.03 million in 2025 and is expected to reach $1390.77 million by 2032 growing at a CAGR of 32.3% during the forecast period. Artificial Intelligence Tumor Evolution Maps are innovative systems designed to study how cancers develop, mutate, and react to different therapies over time. These maps process extensive genomic profiles, medical scans, and patient records to uncover the dynamic nature of tumor progression. By revealing how cancer cells adapt and acquire drug resistance, they assist researchers in forecasting clinical outcomes and tailoring personalized treatments. Unlike conventional approaches, AI-driven models merge diverse datasets, highlighting subtle interactions within tumor biology that might otherwise remain hidden. This cutting-edge methodology equips oncologists with deeper insights, enabling more accurate therapeutic decisions and offering improved prospects for cancer management.

According to the International Agency for Research on Cancer (IARC), The number of cancer-associated deaths is projected to increase from 7.6 million in 2008 to 13 million in 2030-a rise of approximately 72%.

Market Dynamics:

Driver:

Increasing cancer incidence

The global rise in cancer cases is significantly boosting the demand for AI Tumor Evolution Maps. With more patients being diagnosed, healthcare systems require sophisticated tools to track tumor growth, anticipate changes, and support individualized therapy decisions. AI-based maps allow clinicians to process extensive genomic and clinical datasets, enhancing care management. Increasing awareness of cancer risks and treatment options, along with the growth of various cancer types, further stimulates the adoption of these technologies. This situation drives investment in AI solutions that aid in early detection, precise treatment strategies, and improved patient survival, making them an essential part of modern oncology practices.

Restraint:

High implementation costs

The significant cost of implementing AI Tumor Evolution Maps is a major market restraint. Establishing and maintaining these systems requires heavy investment in computing hardware, software solutions, and skilled professionals. Smaller healthcare facilities often cannot bear these costs, limiting their access to AI-powered tumor mapping. Additional expenses related to software updates, data management, and integration with existing clinical workflows further compound the challenge. These financial barriers can slow market growth, restrict the entry of new competitors, and hinder adoption in developing regions. Despite the advantages of AI-driven tumor evolution tools, high implementation costs remain a critical factor preventing broader utilization across hospitals and clinics worldwide.

Opportunity:

Increasing demand for precision oncology

Rising interest in precision oncology offers strong growth potential for the AI Tumor Evolution Maps market. Both patients and healthcare providers are increasingly focused on personalized treatment approaches that consider individual tumor characteristics, genetic alterations, and therapy outcomes. AI-enabled tumor evolution platforms can analyze complex information, detect subtle patterns, and generate actionable recommendations for customized treatments. As precision medicine gains traction, the need for AI tools that support accurate prognosis, optimize therapy, and anticipate resistance is growing. Providers of AI-based tumor mapping solutions can capitalize on this demand to expand their market reach, improve patient care, and advance the implementation of targeted cancer therapies globally.

Threat:

Competition from traditional methods

Traditional cancer diagnostic and monitoring techniques present a threat to the AI Tumor Evolution Maps market. Traditional approaches such as biopsies, pathology examinations, and standard imaging techniques are well-established, reliable, and generally more affordable compared to AI-driven platforms. Healthcare providers may hesitate to implement new AI technologies due to concerns over accuracy, workflow integration, and training requirements. Resistance to adopting novel approaches can slow the market penetration of AI tumor evolution solutions, especially in resource-limited regions. Traditional methods also benefit from regulatory approval experience and extensive clinical validation. As a result, AI platforms face strong competition from conventional practices, which may limit adoption despite the potential for technological improvements.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the AI Tumor Evolution Maps market. Many hospitals and research centers experienced disruptions in routine cancer care, including screenings, therapies, and clinical studies, leading to a temporary decline in demand for AI-based tumor mapping systems. Supply chain delays further hindered the deployment of necessary hardware and software. Conversely, the pandemic accelerated the integration of digital health solutions, telemedicine, and AI analytics, demonstrating the critical role of remote monitoring and predictive healthcare tools. Consequently, although short-term market growth slowed, COVID-19 underscored the importance of AI tumor evolution platforms in improving patient management, enhancing decision-making, and strengthening healthcare resilience.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to account for the largest market share during the forecast period. This dominance is due to the high prevalence of breast cancer worldwide and significant investments in AI research aimed at improving breast cancer care. AI-driven tools, including deep learning models and sophisticated imaging technologies, have significantly improved early detection, tailored treatment strategies, and ongoing monitoring of tumor development in breast cancer patients. As AI technologies continue to evolve, their application in breast cancer is expected to expand, reinforcing its leading role in the AI tumor mapping market.

The AI & health tech startups segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the AI & health tech startups segment is predicted to witness the highest growth rate. This growth is fueled by innovations in personalized medicine, where AI customizes treatments based on individual genetic information, lifestyle, and health history. Moreover, these startups are pioneering the integration of AI with genomics and clinical data, providing novel solutions that significantly improve the precision and effectiveness of cancer diagnostics and treatment strategies. Their adaptability and emphasis on advanced technologies establish them as key players in the rapidly advancing field of AI-powered oncology.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by factors such as cutting-edge healthcare facilities, significant R&D investments, and a high incidence of cancer. Government support, including favorable regulations and initiatives, has further accelerated the adoption of AI technologies in oncology. The concentration of prominent technology firms and prestigious medical institutions in the region has created a robust ecosystem for the advancement and implementation of AI-based cancer diagnostic and treatment solutions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. This surge is attributed to factors such as a rising prevalence of cancer, improvements in healthcare infrastructure, and an increased adoption of artificial intelligence in medical diagnostics. Nations like China, Japan, and India are making substantial investments in AI research and development, creating a favorable environment for market growth. Furthermore, partnerships between healthcare institutions and technology companies are facilitating the integration of AI solutions in oncology. These factors collectively position the APAC region as a key player in the global AI Tumor Evolution Maps market.

Key players in the market

Some of the key players in AI Tumor Evolution Maps Market include Azra AI, Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Median Technologies, PathAI, Paige, AstraZeneca, CancerIQ, X-ZELL, MNM Bioscience, Biotome, Immunai, OncoHost, Tempus and 1Cell.Ai.

Key Developments:

In August 2025, GE HealthCare and Gentuity LLC plan to collaborate on commercial activities to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology. The collaboration is intended to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology.

In April 2025, Azra AI and Elekta announce partnership to enhance cancer registry operations with AI-powered automation. This partnership combines Azra AI's real-time patient identification and workflow automation with Elekta's next-generation cancer registry software, Elekta ONE Registry Informatics*. The combined technologies will enable cancer registry teams to automate cancer casefinding, streamline data ingestion, increase reporting accuracy, and ensure compliance with national and international standards.

In January 2025, Siemens Healthineers has entered into a technology licensing agreement with Kromek Group Plc to enable the in-house production of cadmium zinc telluride (CZT) material for gamma ray detectors used in single-photon emission computed tomography (SPECT) systems. Under the terms of the agreement, Siemens Healthineers will license Kromek's technology to produce CZT, which will extend its research, development, and manufacturing capabilities to allow for a potential future line of gamma ray detectors for multi-modal SPECT systems.

Cancer Types Covered:

  • Brain Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Hematologic Malignancies
  • Rare & Pediatric Cancers
  • Other Cancer Types

Technologies Covered:

  • Imaging-Based Mapping (MRI, CT, PET)
  • Genomic and Transcriptomic Mapping
  • AI-Powered Predictive Modeling
  • Multi-Omics Integration Platforms
  • Spatial Transcriptomics
  • Digital Twin Modeling
  • Federated Learning & Privacy-Preserving AI

Applications Covered:

  • Diagnosis and Early Detection
  • Prognosis and Risk Assessment
  • Treatment Planning
  • Drug Development and Clinical Trials
  • Tumor Monitoring and Recurrence Prediction
  • Biomarker Discovery
  • Patient Stratification for Immunotherapy

End Users Covered:

  • Hospitals and Clinics
  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Academic Institutions
  • Diagnostic Laboratories
  • AI & Health Tech Startups

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global AI Tumor Evolution Maps Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Brain Cancer
  • 5.3 Lung Cancer
  • 5.4 Breast Cancer
  • 5.5 Colorectal Cancer
  • 5.6 Prostate Cancer
  • 5.7 Pancreatic Cancer
  • 5.8 Hematologic Malignancies
  • 5.9 Rare & Pediatric Cancers
  • 5.10 Other Cancer Types

6 Global AI Tumor Evolution Maps Market, By Technology

  • 6.1 Introduction
  • 6.2 Imaging-Based Mapping (MRI, CT, PET)
  • 6.3 Genomic and Transcriptomic Mapping
  • 6.4 AI-Powered Predictive Modeling
  • 6.5 Multi-Omics Integration Platforms
  • 6.6 Spatial Transcriptomics
  • 6.7 Digital Twin Modeling
  • 6.8 Federated Learning & Privacy-Preserving AI

7 Global AI Tumor Evolution Maps Market, By Application

  • 7.1 Introduction
  • 7.2 Diagnosis and Early Detection
  • 7.3 Prognosis and Risk Assessment
  • 7.4 Treatment Planning
  • 7.5 Drug Development and Clinical Trials
  • 7.6 Tumor Monitoring and Recurrence Prediction
  • 7.7 Biomarker Discovery
  • 7.8 Patient Stratification for Immunotherapy

8 Global AI Tumor Evolution Maps Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Clinics
  • 8.3 Research Institutes
  • 8.4 Pharmaceutical & Biotechnology Companies
  • 8.5 Academic Institutions
  • 8.6 Diagnostic Laboratories
  • 8.7 AI & Health Tech Startups

9 Global AI Tumor Evolution Maps Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Azra AI
  • 11.2 Siemens Healthineers AG
  • 11.3 GE HealthCare
  • 11.4 NVIDIA Corporation
  • 11.5 Median Technologies
  • 11.6 PathAI
  • 11.7 Paige
  • 11.8 AstraZeneca
  • 11.9 CancerIQ
  • 11.10 X-ZELL
  • 11.11 MNM Bioscience
  • 11.12 Biotome
  • 11.13 Immunai
  • 11.14 OncoHost
  • 11.15 Tempus
  • 11.16 1Cell.Ai

List of Tables

  • Table 1 Global AI Tumor Evolution Maps Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global AI Tumor Evolution Maps Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 3 Global AI Tumor Evolution Maps Market Outlook, By Brain Cancer (2024-2032) ($MN)
  • Table 4 Global AI Tumor Evolution Maps Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 5 Global AI Tumor Evolution Maps Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 6 Global AI Tumor Evolution Maps Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 7 Global AI Tumor Evolution Maps Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 8 Global AI Tumor Evolution Maps Market Outlook, By Pancreatic Cancer (2024-2032) ($MN)
  • Table 9 Global AI Tumor Evolution Maps Market Outlook, By Hematologic Malignancies (2024-2032) ($MN)
  • Table 10 Global AI Tumor Evolution Maps Market Outlook, By Rare & Pediatric Cancers (2024-2032) ($MN)
  • Table 11 Global AI Tumor Evolution Maps Market Outlook, By Other Cancer Types (2024-2032) ($MN)
  • Table 12 Global AI Tumor Evolution Maps Market Outlook, By Technology (2024-2032) ($MN)
  • Table 13 Global AI Tumor Evolution Maps Market Outlook, By Imaging-Based Mapping (MRI, CT, PET) (2024-2032) ($MN)
  • Table 14 Global AI Tumor Evolution Maps Market Outlook, By Genomic and Transcriptomic Mapping (2024-2032) ($MN)
  • Table 15 Global AI Tumor Evolution Maps Market Outlook, By AI-Powered Predictive Modeling (2024-2032) ($MN)
  • Table 16 Global AI Tumor Evolution Maps Market Outlook, By Multi-Omics Integration Platforms (2024-2032) ($MN)
  • Table 17 Global AI Tumor Evolution Maps Market Outlook, By Spatial Transcriptomics (2024-2032) ($MN)
  • Table 18 Global AI Tumor Evolution Maps Market Outlook, By Digital Twin Modeling (2024-2032) ($MN)
  • Table 19 Global AI Tumor Evolution Maps Market Outlook, By Federated Learning & Privacy-Preserving AI (2024-2032) ($MN)
  • Table 20 Global AI Tumor Evolution Maps Market Outlook, By Application (2024-2032) ($MN)
  • Table 21 Global AI Tumor Evolution Maps Market Outlook, By Diagnosis and Early Detection (2024-2032) ($MN)
  • Table 22 Global AI Tumor Evolution Maps Market Outlook, By Prognosis and Risk Assessment (2024-2032) ($MN)
  • Table 23 Global AI Tumor Evolution Maps Market Outlook, By Treatment Planning (2024-2032) ($MN)
  • Table 24 Global AI Tumor Evolution Maps Market Outlook, By Drug Development and Clinical Trials (2024-2032) ($MN)
  • Table 25 Global AI Tumor Evolution Maps Market Outlook, By Tumor Monitoring and Recurrence Prediction (2024-2032) ($MN)
  • Table 26 Global AI Tumor Evolution Maps Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
  • Table 27 Global AI Tumor Evolution Maps Market Outlook, By Patient Stratification for Immunotherapy (2024-2032) ($MN)
  • Table 28 Global AI Tumor Evolution Maps Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global AI Tumor Evolution Maps Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
  • Table 30 Global AI Tumor Evolution Maps Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 31 Global AI Tumor Evolution Maps Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 32 Global AI Tumor Evolution Maps Market Outlook, By Academic Institutions (2024-2032) ($MN)
  • Table 33 Global AI Tumor Evolution Maps Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global AI Tumor Evolution Maps Market Outlook, By AI & Health Tech Startups (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.